Antisense oligonucleotide agents for treating conditions associated with nlrp3/nlrp1 expression or activation
AssigneeMolecular Axiom, LLC
InventorsLishan CHEN, Bohan JIN, Timothy WONG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antisense oligonucleotide compounds and compositions (e.g., pharmaceutical compositions) targeting NLRP3 and/or NLRP1 mRNA, and methods for treating diseases or conditions associated with NLRP3 and/or NLRP1 mRNA expression or NLRP3 and/or NLRP1 inflammasome activation. Exemplary conditions for which the compounds and compositions find use include inflammatory diseases such as neurodegenerative and autoimmune diseases, among others.
Claims44
A compound comprising an antisense oligonucleotide of 10 to 30 nucleotides in length and comprising at least 8 contiguous nucleotides of any one of SEQ ID NOs:1 to SEQ ID NO:52, and which inhibits the expression of NLRP3 and/or NLRP1 mRNA.
Dependencies are inferred from the claim text.